Trametinib 2 mg

DRUG4 trials

Sponsors

GlaxoSmithKline, Jonsson Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Olivia Newton-John Cancer Research Institute

Conditions

CancerKRAS Gene MutationNon Small Cell Lung CancerProgressive Metastatic Castrate Resistant Prostate CancerThyroid Cancer

Phase 1

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

WithdrawnNCT02292732

GlaxoSmithKlineCancer

Start: 2016-02-29End: 2017-05-31Updated: 2016-01-26

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

CompletedNCT03704688

Memorial Sloan Kettering Cancer CenterKRAS Gene Mutation, Non Small Cell Lung Cancer

Start: 2018-10-09End: 2022-02-04Updated: 2025-05-16

Phase 2

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

Olivia Newton-John Cancer Research InstituteThyroid Cancer

Start: 2022-07-14End: 2025-12-30Target: 80Updated: 2023-10-31

Unknown Phase

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Jonsson Comprehensive Cancer CenterProgressive Metastatic Castrate Resistant Prostate Cancer

Updated: 2019-01-16